...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Comparison of the Effects on Rib Fracture between the Traditional Japanese Medicine Jidabokuippo and Nonsteroidal Anti-Inflammatory Drugs: A Randomized Controlled Trial
【24h】

Comparison of the Effects on Rib Fracture between the Traditional Japanese Medicine Jidabokuippo and Nonsteroidal Anti-Inflammatory Drugs: A Randomized Controlled Trial

机译:比较传统中药吉大骨补足药和非甾体类抗炎药对肋骨骨折的影响:一项随机对照试验

获取原文
获取原文并翻译 | 示例
           

摘要

Jidabokuippo is a traditional Japanese medicine used for contusion-induced swelling and pain. This open multicenter randomized study was designed to compare the efficacies of jidabokuippo and nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with rib fracture by analyzing the treatment duration. Our study involved 170 rib fracture patients capable of oral ingestion divided randomly into 2 groups: the jidabokuippo and NSAID groups. We compared the duration of treatment and healthcare expenditure between these 2 groups. Medication was continued in both groups until the visual analogue scale score decreased to less than 50% of the pretreatment score. We excluded the patients in whom medication was prematurely discontinued. We analyzed 81 patients belonging to the jidabokuippo and NSAIDs groups. No significant intergroup differences were observed in age, gender, severity (injury severity score), and presence/absence of underlying disease. The treatment duration was significantly shorter in the jidabokuippo group than in the NSAIDs group (P = 0.0003). Healthcare expenditure was significantly lower in the jidabokuippo group than in the NSAIDs group {P < 0.0001). Our results suggest that compared to NSAIDs, jidabokuippo can shorten the duration of treatment in patients with rib fracture and is a promising analgesic agent based on the medical economic viewpoint.
机译:Jidabokuippo是一种传统的日本药,可用于挫伤引起的肿胀和疼痛。这项开放式多中心随机研究旨在通过分析治疗持续时间,比较吉达布波波和非甾体类抗炎药(NSAID)在肋骨骨折患者中的疗效。我们的研究涉及170例能够​​口服的肋骨骨折患者,将其随机分为两组:吉达布库波波组和NSAID组。我们比较了这两组患者的治疗时间和医疗保健支出。两组均继续用药,直到视觉模拟量表评分降至治疗前评分的50%以下。我们排除了过早停药的患者。我们分析了jidabokuippo和NSAIDs组的81名患者。在年龄,性别,严重程度(损伤严重程度评分)以及是否存在基础疾病方面,未观察到明显的组间差异。吉达波库波组的治疗持续时间明显短于非甾体抗炎药组(P = 0.0003)。吉达博库波波组的医疗保健支出明显低于非甾体抗炎药组(P <0.0001)。我们的研究结果表明,与NSAIDs相比,吉达布波马可以缩短肋骨骨折患者的治疗时间,并且从医学经济学的角度来看,它是一种有希望的止痛药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号